抗VEGF药物治疗新生血管性眼病的现状与展望

Anti-Vascular Endothelial Grow Factor Drugs for Ocular Neovascularization Dieases: Status and Prospect

新生血管性眼病是目前临床关注度最高、研究最活跃的一类眼部疾病,如不及时加以干涉,将会对视力造成严重损害。传统的治疗手段,如激光、手术等虽能缓解病程的进展,但不可避免地会损害健康组织。以血管内皮生长因子(VEGF)作为靶点,玻璃体腔内注射抗VEGF药物使新生血管性眼病的治疗进入了新纪元。目前抗VEGF药物已广泛用于眼科临床研究,并造福了数以万计的患者,但作为一个新药仍需综合评价其临床应用时可能存在的问题。

One of the focuses in eye disease study is ocular neovascularization,which will lead to severe vision impairment without timely treatment. Laser and surgery as traditional treatments to the disease can slow down the progression,but damage healthy tissue inevitably at the same time. Aiming at vascular endothelial growth factor（ VEGF）,intravitreal injection of anti-VEGF has ushered the treatment of ocular neovascularization into a new era. Now theanti-VEGF drug is widely used and benefits many patients,but there are still many questions about its clinical application needing comprehensive evaluation.